Previous close | 9.77 |
Open | 9.77 |
Bid | 10.03 x 400 |
Ask | 10.10 x 100 |
Day's range | 9.77 - 10.14 |
52-week range | 7.51 - 12.44 |
Volume | |
Avg. volume | 165,951 |
Market cap | 463.079M |
Beta (5Y monthly) | 0.73 |
PE ratio (TTM) | 27.16 |
EPS (TTM) | 0.37 |
Earnings date | 25 Apr 2024 - 29 Apr 2024 |
Forward dividend & yield | 0.32 (3.18%) |
Ex-dividend date | 09 Apr 2024 |
1y target est | 12.25 |
STERIS (STE) is expected to have witnessed the normalization of the Healthcare backlog, as the company is currently able to ship at a faster pace than the receipt of new orders.
Edwards Lifesciences, DexCom and STERIS have been highlighted in this Industry Outlook article.
The Zacks Medical - Instruments industry is expected to gain from the rising adoption of smart healthcare options, including genAI. However, supply issues and staffing shortages continue to disrupt growth. EW, DXCM and STE appear well-poised to brave the challenges.